Inclusion Criteria:

- Males or non-pregnant, non-breastfeeding females 18 years-of-age or older with
confirmed hematological malignancy, without known or clinically suspected CNS
involvement, that is refractory to available therapy or for which there is no
available therapy.

- Karnofsky performance score ≥60

- Life expectancy of at least 3 months.

- Adequate baseline laboratory assessments

Exclusion Criteria:

- Currently receiving anticancer therapy or have received anticancer therapy within the
past 28 days or 5 half-lives of the anticancer therapy

- The need for treatment with medications with clinically-relevant metabolism by the
cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of
SNX-5422

- At increased risk for developing prolonged QT interval, including hypokalemia or
hypomagnesemia, unless corrected to within normal limits prior to first dose of SNX-•
Chronic diarrhea.

- Gastrointestinal diseases or conditions that could affect drug absorption, including
gastric bypass.

- Gastrointestinal diseases that could alter the assessment of safety, including
irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic
coloproctitis.

- History of documented adrenal dysfunction not due to malignancy.

- Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).

- History of chronic liver disease